Chevilly-Larue, France

Marie-Odile Lonchampt



Average Co-Inventor Count = 3.3

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2003-2006

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Work of Inventor Marie-Odile Lonchampt

Introduction

Marie-Odile Lonchampt, a talented inventor based in Chevilly-Larue, France, has made significant contributions to the field of cancer treatment through his groundbreaking inventions. With a total of 3 patents to his name, Lonchampt has been at the forefront of developing novel therapeutic solutions for combating cancer.

Latest Patents

One of Lonchampt's latest patents revolves around a product that inhibits the transduction of G heterotrimeric protein signals, combined with other anti-cancer agents such as farnesyltransferase inhibitors, taxol, or gemcitabin. This innovation allows for simultaneous, separate, or prolonged therapeutic use in cancer treatment. Another patent focuses on the use of cysteine derivatives in preparing a medicament to treat pathologies resulting from the formation of the heterotrimeric G protein.

Career Highlights

Lonchampt is associated with the Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), where he brings his inventive ideas to life. His dedication to research and development has led to the successful filing of multiple patents, showcasing his commitment to advancing healthcare through innovation.

Collaborations

Throughout his career, Lonchampt has collaborated with esteemed professionals in the field, including Thomas D Gordon and Grégoire Prevost. These collaborations have fueled creative thinking and resulted in the development of cutting-edge solutions for cancer treatment.

Conclusion

Inventor Marie-Odile Lonchampt's passion for innovation and his relentless pursuit of novel therapeutic approaches have positioned him as a key figure in the field of cancer research. His patents reflect his deep understanding of medical science and his unwavering commitment to improving patient outcomes in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…